Trovagene (TROV) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Trovagene Announces First Quarter 2016 Financial Results
May 10, 2016 4:06 PM EDTSAN DIEGO, May 10, 2016 /PRNewswire/ --Â Trovagene, Inc. (NASDAQ:Â TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2016.
"I'm thrilled to join Trovagene to drive the development and commercialization of the Company's differentiated molecular diagnostic platform, and to improve the care of cancer patients," said Bill Welch, chief executive officer of Trovagene. "Liquid biopsy for cancer monitoring offers tremendous potential, and our strong balance sheet positions us to execute on our business plan and create... More
